CINXE.COM

<!DOCTYPE html><html lang="en"><head><meta charSet="utf-8"/><link rel="icon" type="image/png" href="https://assets.brighttalk.com/images/favicon.ico?nocache=1"/><link rel="apple-touch-icon" href="https://assets.brighttalk.com/images/favicon-apple-touch-icon.png?nocache=1"/><link rel="canonical" href="https://www.brighttalk.com/webcast/10519/612992"/><title>Evaluating Analytical Strategies to Quantify Capsid Titre...</title><meta name="description" content="Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development Tr..."/><meta property="og:type" content="website"/><meta name="og:title" property="og:title" content="Evaluating Analytical Strategies to Quantify Capsid Titre..."/><meta name="og:description" property="og:description" content="Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development Traditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies."/><meta property="og:site_name" content="BrightTALK"/><meta property="og:url" content="https://www.brighttalk.com/webcast/10519/612992"/><meta name="brighttalk-channel-id" content="10519"/><meta name="brighttalk-page-architecture" content="react"/><meta name="brighttalk-page-name" content="webcast"/><meta name="brighttalk-content-status" content="recorded"/><meta name="brighttalk-community" content="Life Sciences"/><meta name="brighttalk-community-parent" content="Healthcare"/><meta name="twitter:card" content="summary"/><meta name="twitter:title" content="Evaluating Analytical Strategies to Quantify Capsid Titre..."/><meta name="twitter:description" content="Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development Traditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies."/><meta name="twitter:site" content="BrightTALK"/><meta name="twitter:creator" content=""/><meta property="og:image" content="https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360"/><meta name="twitter:image" content="https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360"/><meta name="viewport" content="initial-scale=1.0, width=device-width"/><meta name="robots" content="index,follow"/><script type="application/ld+json">{"@context":"https://schema.org","@type":"Event","name":"Evaluating Analytical Strategies to Quantify Capsid Titre...","description":"Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development\n\nTraditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.","about":"Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development\n\nTraditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.","startDate":"2024-10-30T14:00:00Z","endDate":"2024-10-30T14:01:00.000Z","url":"https://www.brighttalk.com/webcast/10519/612992","duration":"PT0H1M0S","location":{"@type":"VirtualLocation","name":"BrightTALK","url":"https://www.brighttalk.com/webcast/10519/612992","description":"Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development\n\nTraditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.","image":"https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360"},"image":"https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360","performer":"Dr. Marilia Barros, PhD, Principal Scientist Biologics & Gene Therapy Drug Product Development at Regeneron and Dr. Matt Ranaghan, Senior Applications Scientist, at Refeyn","organizer":{"@type":"Organization","name":"BioPharma Webinars","description":"BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.","url":"https://www.brighttalk.com/channel/10519"},"eventAttendanceMode":"OnlineEventAttendanceMode","eventStatus":"EventScheduled","aggregateRating":{"@type":"AggregateRating","bestRating":"5","worstRating":"1","ratingValue":5,"ratingCount":3}}</script><script async="" src="https://unpkg.com/date-time-format-timezone@latest/build/browserified/date-time-format-timezone-complete-min.js"></script><style type="text/css"> #cmp-banner { position: fixed; bottom: 0; left: 0; z-index: 1200; } @media (min-width: 960px) { #cmp-banner { bottom: 20px; left: 20px; } } #cmp-banner, #cmp-banner > div, #cmp-banner iframe { width: 300px; height: 275px; } #cmp-banner:empty { display: none; } </style><script type="text/javascript"> "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r<t;r++)n[r]=arguments[r];if(!n.length)return o;"setGdprApplies"===n[0]?n.length>3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); (function () { var e = false; var c = window; var t = document; function r() { if (!c.frames["__uspapiLocator"]) { if (t.body) { var a = t.body; var e = t.createElement("iframe"); e.style.cssText = "display:none"; e.name = "__uspapiLocator"; a.appendChild(e) } else { setTimeout(r, 5) } } } r(); function p() { var a = arguments; __uspapi.a = __uspapi.a || []; if (!a.length) { return __uspapi.a } else if (a[0] === "ping") { a[2]({ gdprAppliesGlobally: e, cmpLoaded: false }, true) } else { __uspapi.a.push([].slice.apply(a)) } } function l(t) { var r = typeof t.data === "string"; try { var a = r ? JSON.parse(t.data) : t.data; if (a.__cmpCall) { var n = a.__cmpCall; c.__uspapi(n.command, n.parameter, function (a, e) { var c = { __cmpReturn: { returnValue: a, success: e, callId: n.callId } }; t.source.postMessage(r ? JSON.stringify(c) : c, "*") }) } } catch (a) { } } if (typeof __uspapi !== "function") { c.__uspapi = p; __uspapi.msgHandler = l; c.addEventListener("message", l, false) } })(); window.__gpp_addFrame=function(e){if(!window.frames[e])if(document.body){var t=document.createElement("iframe");t.style.cssText="display:none",t.name=e,document.body.appendChild(t)}else window.setTimeout(window.__gpp_addFrame,10,e)},window.__gpp_stub=function(){var e=arguments;if(__gpp.queue=__gpp.queue||[],__gpp.events=__gpp.events||[],!e.length||1==e.length&&"queue"==e[0])return __gpp.queue;if(1==e.length&&"events"==e[0])return __gpp.events;var t=e[0],p=e.length>1?e[1]:null,s=e.length>2?e[2]:null;if("ping"===t)p({gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}},!0);else if("addEventListener"===t){"lastId"in __gpp||(__gpp.lastId=0),__gpp.lastId++;var n=__gpp.lastId;__gpp.events.push({id:n,callback:p,parameter:s}),p({eventName:"listenerRegistered",listenerId:n,data:!0,pingData:{gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}}},!0)}else if("removeEventListener"===t){for(var a=!1,i=0;i<__gpp.events.length;i++)if(__gpp.events[i].id==s){__gpp.events.splice(i,1),a=!0;break}p({eventName:"listenerRemoved",listenerId:s,data:a,pingData:{gppVersion:"1.1",cmpStatus:"stub",cmpDisplayStatus:"hidden",signalStatus:"not ready",supportedAPIs:["2:tcfeuv2","5:tcfcav1","6:uspv1","7:usnatv1","8:uscav1","9:usvav1","10:uscov1","11:usutv1","12:usctv1"],cmpId:0,sectionList:[],applicableSections:[],gppString:"",parsedSections:{}}},!0)}else"hasSection"===t?p(!1,!0):"getSection"===t||"getField"===t?p(null,!0):__gpp.queue.push([].slice.apply(e))},window.__gpp_msghandler=function(e){var t="string"==typeof e.data;try{var p=t?JSON.parse(e.data):e.data}catch(e){p=null}if("object"==typeof p&&null!==p&&"__gppCall"in p){var s=p.__gppCall;window.__gpp(s.command,(function(p,n){var a={__gppReturn:{returnValue:p,success:n,callId:s.callId}};e.source.postMessage(t?JSON.stringify(a):a,"*")}),"parameter"in s?s.parameter:null,"version"in s?s.version:"1.1")}},"__gpp"in window&&"function"==typeof window.__gpp||(window.__gpp=window.__gpp_stub,window.addEventListener("message",window.__gpp_msghandler,!1),window.__gpp_addFrame("__gppLocator")); window._sp_queue = []; window._sp_ = { config: { accountId: 370, baseEndpoint: 'https://cdn.privacy-mgmt.com', usnat: { includeUspApi: true }, gdpr: { }, events: { onMessageChoiceSelect: function (message_type, choice_id, choice_type_id) { // Code to make 'OK' and 'X' buttons work in the CPPA banner if(message_type === 'ccpa'){ console.log(choice_type_id); if(choice_type_id===11||choice_type_id===15){ document.getElementById("cmp-banner").style.display = "none"; } } }, onMessageReady: function() { console.log('[event] onMessageReady', arguments); }, onMessageChoiceError: function() { console.log('[event] onMessageChoiceError', arguments); }, onPrivacyManagerAction: function() { console.log('[event] onPrivacyManagerAction', arguments); }, onPMCancel: function() { console.log('[event] onPMCancel', arguments); }, onMessageReceiveData: function() { console.log('[event] onMessageReceiveData', arguments); }, onSPPMObjectReady: function() { console.log('[event] onSPPMObjectReady', arguments); }, onConsentReady: function (message_type, choice_type_id, choice_id, consentUUID, euconsent) { console.log('[event] onConsentReady', arguments); // Code to make 'OK' and 'X' buttons work in the CPPA banner if(message_type === 'usnat'){ if(document.getElementsByClassName('close-button')||document.getElementsByClassName('sp_choice_type_Accept')){ document.getElementById("cmp-banner").style.display = "none"; } } }, onError: function() { console.log('[event] onError', arguments); }, } } } </script><script src="https://cdn.privacy-mgmt.com/unified/wrapperMessagingWithoutDetection.js" async=""></script><meta name="next-head-count" content="31"/><script type="text/javascript"> window.dataLayer = window.dataLayer || []; function gtag() { dataLayer.push(arguments); } //default behavior gtag('consent', 'default', { 'ad_storage': 'granted', 'analytics_storage': 'granted', 'wait_for_update': 500 }); //behavior specific for end-users in the EEA gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'region': ['BE', 'BG', 'CZ', 'DK', 'CY', 'LV', 'LT', 'LU', 'ES', 'FR', 'HR', 'IT', 'PL', 'PT', 'RO', 'SI', 'HU', 'MT', 'NL', 'AT', 'IS', 'LI', 'NO', 'SK', 'FI', 'SE', 'DE', 'EE', 'IE', 'EL'], 'wait_for_update': 500 }); </script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push( {'gtm.start': new Date().getTime(),event:'gtm.js'} );var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-NCXH7DF');</script><meta name="brighttalk-build"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Light.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Regular.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Bold.woff" as="font" type="font/woff" crossorigin="true"/><link rel="preload" href="https://assets.brighttalk.com/fonts/Roboto-Medium.woff" as="font" type="font/woff" crossorigin="true"/><script type="module" src="https://www.brighttalk.com/globalauth-helpercomponent/globalauth-helpercomponent.esm.js"></script><link rel="preload" href="/webcast/_next/static/css/f27ee2d0379f6a23.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/f27ee2d0379f6a23.css" data-n-g=""/><link rel="preload" href="/webcast/_next/static/css/b4f323b4af080a55.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/b4f323b4af080a55.css" data-n-p=""/><link rel="preload" href="/webcast/_next/static/css/ce5fea244d2c7257.css" as="style"/><link rel="stylesheet" href="/webcast/_next/static/css/ce5fea244d2c7257.css"/><noscript data-n-css=""></noscript><script defer="" nomodule="" src="/webcast/_next/static/chunks/polyfills-c67a75d1b6f99dc8.js"></script><script defer="" src="/webcast/_next/static/chunks/479.00bec7571fc3660a.js"></script><script src="/webcast/_next/static/chunks/webpack-bb6ce3c3c2c718cd.js" defer=""></script><script src="/webcast/_next/static/chunks/framework-aeb85a5e071ca0cb.js" defer=""></script><script src="/webcast/_next/static/chunks/main-5dfda2bd9643ffef.js" defer=""></script><script src="/webcast/_next/static/chunks/pages/_app-e6824c9da32635bf.js" defer=""></script><script src="/webcast/_next/static/chunks/28455a0b-43eb64133fbfdb7c.js" defer=""></script><script src="/webcast/_next/static/chunks/161-21e61a853b21e681.js" defer=""></script><script src="/webcast/_next/static/chunks/437-a473e5906be61f8a.js" defer=""></script><script src="/webcast/_next/static/chunks/9-da12f2150edc51cc.js" defer=""></script><script src="/webcast/_next/static/chunks/pages/%5BchannelId%5D/%5BwebcastId%5D-fbe755c2b60759f0.js" defer=""></script><script src="/webcast/_next/static/1797/_buildManifest.js" defer=""></script><script src="/webcast/_next/static/1797/_ssgManifest.js" defer=""></script><style id="__jsx-3123759138">.previewImg.jsx-3123759138{background:url(https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360)center center no-repeat;-webkit-filter:blur(4rem)grayscale(30%);filter:blur(4rem)grayscale(30%);opacity:.17;-webkit-background-size:cover;-moz-background-size:cover;-o-background-size:cover;background-size:cover;width:100%;height:100%;-webkit-transform:scale(1.1);-moz-transform:scale(1.1);-ms-transform:scale(1.1);-o-transform:scale(1.1);transform:scale(1.1)}</style> <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="JVT9R-JD38W-BPCAY-8MYGM-PYXBG",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"JVT9R-JD38W-BPCAY-8MYGM-PYXBG";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="",a="bdpnbeqxzkcqqz5tc63a-f-754d72458-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"87120","ak.ai":parseInt("390532",10),"ak.ol":"0","ak.cr":3,"ak.ipv":4,"ak.proto":"http/1.1","ak.rid":"377c404d","ak.r":47863,"ak.a2":n,"ak.m":"b","ak.n":"essl","ak.bpcip":"8.222.208.0","ak.cport":36810,"ak.gh":"23.54.158.70","ak.quicv":"","ak.tlsv":"tls1.2","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"reno","ak.t":"1739790262","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==IIApRHyukFOVj8UURM+LjTrDjK0YYkYn2s6HuFw1trMPz4XDzwnkl59yAZ4nEuPIX2uwnMBnMbbqs2JgsWvk/niqB3cKHU17SIr7tkXrc6iBXV6Nxd0EuiTfe79c12x3LkN+/4Zf6jUWNh3x3Lyq/t86mCPecb7Dlq4sp4CIg5uiXMKmuvTObum8SZ9M5UWRB+hR/FMZrcOv4f3M26q/4KxmU5resocr/LfUkdulFzbNUt9BdGs2801K0BfHOcx47/R1J2TwEfGOnEQJFdakwFqGK8M2Sdtoi1Q9vSznr01GkejEqfGNGY2rYihXwcEmntYrJElGqn7ZdQUUM9fRG71I1y1b3AYhW1F/YeeKCysK99as6JjQRlda9wndsi82LXI/2nifXzVCgRqXEEuOroSfvfQgXkwhP9+uz6EbHrU=","ak.pv":"291","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-NCXH7DF" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><div class="global-informa-banner"><script src="https://www.brighttalk.com/webcomponent/dist/techtarget-informa-banner/techtarget-informa-banner.min.js"></script><style> .global-informa-banner { } </style><techtarget-informa-banner theme="light" language="en"></techtarget-informa-banner></div><div id="__next"> <div class="PageContent_app__Tw3yY"><div id="cmp-banner"></div><div class="ClientHeader_ClientHeader__Yhcmr ClientHeader_ClientHeader-basics__Tkt9O" data-preview-img="https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360" aria-hidden="true" data-bdd="client-header"><div class="jsx-3123759138 previewImg"></div><div class="ClientHeader_ClientHeader--Gradient___ql1Q ClientHeader_ClientHeader-basics__Tkt9O"></div></div><span><div class="global-header"><link rel="modulepreload" href="https://www.brighttalk.com/webcomponent/dist/brighttalk-web-components/brighttalk-web-components.esm.js"/><style> .global-header { background-color: white; min-height: 106px; margin-bottom: 30px; } </style></div></span><div class="Container_Container__cJtME PageContent_Player-Content__cuHLP"><main class="PageContent_Player-Content-Main__dT2hM" id="bt-player-content-main"><section class="Section_Section30__FyFjI"><h1 data-bdd="player-webcast-title">Evaluating Analytical Strategies to Quantify Capsid Titre...</h1><section class="Section_Section10__MY7SZ WebcastHeader_WebcastHeader-Subheader-Container__eoyOs" data-bdd="player-webcast-content"><div class="WebcastHeader_WebcastHeader-Subheader__2hOd6"><time class="WebcastHeader_WebcastHeader-Duration__Ojp_n" data-bdd="player-webcast-duration" dateTime="60m"><span>Duration: </span><span>60 mins</span></time></div><div class="WebcastHeader_WebcastHeader-Extra__mYsCW"></div></section><section class="Section_Section40__iljNL DefaultWebcastContent_DefaultWebcastContent--pad-right__m0r9W"><div class="PlayerPlaceholder_outer__erL98" data-bdd="player-placeholder"><div class="PlayerPlaceholder_PlayerPlaceholder__E0yEP" id="default-placeholder"><div style="--aspect-ratio:(16/9)" data-bdd="thumbnail-container" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--small__tLn5m PlayerPlaceholder_PlayerPlaceholder-ThumbnailIE__p2acC PlayerPlaceholder_PlayerPlaceholder--max-height__ylfXH PlayerPlaceholder_PlayerNoCrusor__AAgzp"><img src="https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640&height=360" alt="" class="Thumbnail_thumbnail-img__Odh48" data-bdd="player-placeholder-thumbnail" width="647" height="364"/></div></div></div></section><section data-bdd="player-details"><article class="DefaultWebcastContent_DefaultWebcastContent-article__NVTL1"><h2 class="DefaultWebcastContent_DefaultWebcastContent-Header3__AZoDj"><div data-bdd="player-channel-logo" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--borderless__hCROE Thumbnail_thumbnail--bg-transparent__YK03i DefaultWebcastContent_DefaultWebcastContent-ChannelLogo__PbB1y"><img src="https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300&height=300" alt="Logo" class="Thumbnail_thumbnail-img__Odh48" width="40" height="40"/></div><span>Presented by</span></h2><p class="DefaultWebcastContent_DefaultWebcastContent-P__e8prc" data-bdd="player-presenter">Dr. Marilia Barros, PhD, Principal Scientist Biologics & Gene Therapy Drug Product Development at Regeneron and Dr. Matt Ranaghan, Senior Applications Scientist, at Refeyn</p></article><article><h2 class="DefaultWebcastContent_DefaultWebcastContent-Header3__AZoDj">About this talk</h2><div class="DefaultWebcastContent_DefaultWebcastContent-P__e8prc" data-bdd="player-body"><div class="Markdown_Markdown__kIRZG">Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development Traditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.</div></div></article></section></section><section class="Section_Section30__FyFjI RelatedTopics_RelatedTopics__J973v" data-bdd="related-topic"><div class="RelatedTopics_RelatedTopics-Label__Qc2fT" data-bdd="related-topic-header">Related topics:</div><div class="RelatedTopics_RelatedTopics-Items__VQabW" data-bdd="related-topic-items"><a href="https://www.brighttalk.com/topic/gene-therapy" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-0-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-0-text">Gene Therapy</div></a><a href="https://www.brighttalk.com/topic/elisa" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-1-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-1-text">ELISA</div></a><a href="https://www.brighttalk.com/topic/aav-drug-product" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-2-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-2-text">AAV Drug Product</div></a><a href="https://www.brighttalk.com/topic/capsid-titre" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-3-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-3-text">Capsid Titre</div></a><a href="https://www.brighttalk.com/topic/biologics" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-4-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-4-text">Biologics</div></a><a href="https://www.brighttalk.com/topic/biotherapeutics" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-5-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-5-text">Biotherapeutics</div></a><a href="https://www.brighttalk.com/topic/analytical-methods" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-6-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-6-text">Analytical Methods</div></a><a href="https://www.brighttalk.com/topic/aav-drug-product-development" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-7-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-7-text">AAV Drug Product Development</div></a><a href="https://www.brighttalk.com/topic/biotech" class="RelatedTopics_RelatedTopics-Link__p7ZnJ" data-bdd="related-topic-8-link"><div class="RelatedTopics_RelatedTopics-Item__T42J0" data-bdd="related-topic-8-text">Biotech</div></a></div></section><section class="Section_Section20__bSvI1" data-bdd="channel-info"><div class="SectionHeading_SectionHeading__NkeuR"><h3 data-bdd="channel-info-header" class="">More from this channel</h3></div><div class="ChannelInfo_ChannelInfo__oTF6i"><div class="ChannelInfo_ChannelInfo-Header__Fx7LJ"><a href="https://www.brighttalk.com/channel/10519/" title="Visit BioPharma Webinars's channel" class="ChannelInfo_ChannelInfo-Link__PqzoP globalStyle_hnm___IQTm" data-bdd="channel-info-channel-link"><span class="ChannelInfo_ChannelInfo-Logo__iCERc" data-bdd="channel-info-logo"><div data-bdd="thumbnail-container" class="Thumbnail_thumbnail__nQlEr Thumbnail_thumbnail--borderless__hCROE Thumbnail_thumbnail--bg-transparent__YK03i"><img src="https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300&height=300" alt="BioPharma Webinars logo" class="Thumbnail_thumbnail-img__Odh48" width="40" height="40"/></div></span><span class="ChannelInfo_ChannelInfo-Name__36UR1" data-bdd="channel-info-name">BioPharma Webinars</span></a></div><div class="ChannelInfo_ChannelInfo-Body__Vnmoe"><div class="ChannelInfo_ChannelInfo-Summary__eNUvy"><div class="ChannelInfo_ChannelInfo-SummaryItem--margin__5IC63"><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="calendar" class="svg-inline--fa fa-calendar getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512" data-bdd="item-calendarSolid"><path fill="currentColor" d="M96 32l0 32L48 64C21.5 64 0 85.5 0 112l0 48 448 0 0-48c0-26.5-21.5-48-48-48l-48 0 0-32c0-17.7-14.3-32-32-32s-32 14.3-32 32l0 32L160 64l0-32c0-17.7-14.3-32-32-32S96 14.3 96 32zM448 192L0 192 0 464c0 26.5 21.5 48 48 48l352 0c26.5 0 48-21.5 48-48l0-272z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-upcoming">Upcoming talks (<b>13</b>)</span></div><div class="ChannelInfo_ChannelInfo-SummaryItem--margin__5IC63"><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="play" class="svg-inline--fa fa-play getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 384 512" data-bdd="item-play"><path fill="currentColor" d="M73 39c-14.8-9.1-33.4-9.4-48.5-.9S0 62.6 0 80L0 432c0 17.4 9.4 33.4 24.5 41.9s33.7 8.1 48.5-.9L361 297c14.3-8.7 23-24.2 23-41s-8.7-32.2-23-41L73 39z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-ondemand">On-demand talks (<b>419</b>)</span></div><div><span class="ChannelInfo_ChannelInfo-SummaryIcon__vypMF"><svg aria-hidden="true" focusable="false" data-prefix="fas" data-icon="users" class="svg-inline--fa fa-users getColorClass_text-secondary__5o8tz ChannelInfo_ChannelInfo--grey__D2sZ4" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 640 512" data-bdd="item-users"><path fill="currentColor" d="M144 0a80 80 0 1 1 0 160A80 80 0 1 1 144 0zM512 0a80 80 0 1 1 0 160A80 80 0 1 1 512 0zM0 298.7C0 239.8 47.8 192 106.7 192l42.7 0c15.9 0 31 3.5 44.6 9.7c-1.3 7.2-1.9 14.7-1.9 22.3c0 38.2 16.8 72.5 43.3 96c-.2 0-.4 0-.7 0L21.3 320C9.6 320 0 310.4 0 298.7zM405.3 320c-.2 0-.4 0-.7 0c26.6-23.5 43.3-57.8 43.3-96c0-7.6-.7-15-1.9-22.3c13.6-6.3 28.7-9.7 44.6-9.7l42.7 0C592.2 192 640 239.8 640 298.7c0 11.8-9.6 21.3-21.3 21.3l-213.3 0zM224 224a96 96 0 1 1 192 0 96 96 0 1 1 -192 0zM128 485.3C128 411.7 187.7 352 261.3 352l117.3 0C452.3 352 512 411.7 512 485.3c0 14.7-11.9 26.7-26.7 26.7l-330.7 0c-14.7 0-26.7-11.9-26.7-26.7z"></path></svg></span><span class="ChannelInfo_ChannelInfo-SummaryText__pbg3I" data-bdd="channel-info-subscribers">Subscribers (<b>39830</b>)</span></div></div><div class="ChannelInfo_ChannelInfo-Description__x_HRU" data-bdd="channel-info-body"><span data-bdd="channel-info-description" width="0"><span></span><span>BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.</span><span style="position:fixed;visibility:hidden;top:0;left:0">…</span></span></div></div></div></section></main><aside class="PageContent_Player-Content-Aside__ejqAg"><div class="SidePanel_form-wrapper__XAlVE"><div class="SidePanel_globalauth-wrapper__fRQUj"><div class="SidePanel_spinner-wrapper__vIlwe"><div class="GlobalAuthSkeleton_wrapper__bWg5s"><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_heading__oXy64"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_input__q43DK"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_button__Ji96E"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_privacy-text__U75_Y"><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text___CPXT"></div><div class="GlobalAuthSkeleton_skeleton-loader-item__QXrVE GlobalAuthSkeleton_text-1__a9eLg"></div></div></div></div></div></div></aside></div><div class="global-footer"><style> .global-footer { background-color: rgb(92, 92, 92); min-height: 394px; } </style></div><script src="https://www.brighttalk.com/webcomponent/dist/techtarget-informa-banner/techtarget-informa-footer.js"></script><techtarget-informa-footer theme="light" language="en"></techtarget-informa-footer></div> </div><script id="__NEXT_DATA__" type="application/json">{"props":{"pageProps":{"channelId":"10519","webcastId":"612992","channel":{"id":10519,"statistics":{"upcomingCommunications":"13","liveCommunications":"0","recordedCommunications":"419","subscribers":"39830","viewedSeconds":"230016777"},"channelName":"BioPharma Webinars","channelUrl":"https://www.brighttalk.com/channel/10519","channelDescription":"BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.","visibility":"included","channelImg":"https://cdn.brighttalk.com/ams/california/images/channel/10519/image_873770.jpg?width=300\u0026height=300","locale":"en-US","showAttendees":false,"showShare":true,"showSocial":true},"webcast":{"id":612992,"channel":{"id":10519},"title":"Evaluating Analytical Strategies to Quantify Capsid Titre...","description":"Full title: Evaluating Analytical Strategies to Quantify Capsid Titre: Towards a Platform-Method Approach to Accelerate AAV Drug Product Development\n\nTraditional capsid titre methods rely on ELISA which commonly suffers from long turnaround times, low throughput, and large volume sample requirements. This limits the application of ELISA-based methods to routine analysis, thus requiring development of alternative high-throughput (HTP) capsid titre methods. We have performed a comprehensive assessment on currently available orthogonal capsid titre methods using multiple serotypes at concentration range relevant in IND-enabling preclinical and first-in-human (FIH) clinical studies.","presenter":"Dr. Marilia Barros, PhD, Principal Scientist Biologics \u0026 Gene Therapy Drug Product Development at Regeneron and Dr. Matt Ranaghan, Senior Applications Scientist, at Refeyn","duration":60,"keywords":"Gene Therapy, ELISA, AAV Drug Product, Capsid Titre, Biologics, Biotherapeutics, Analytical Methods, AAV Drug Product Development, Biotech","start":"2024-10-30T14:00:00Z","entryTime":"2024-10-30T13:55:00Z","end":"","status":"recorded","timeZone":"America/New_York","url":"https://www.brighttalk.com/webcast/10519/612992","isGigCancelled":false,"previewImg":"https://cdn.brighttalk.com/ams/california/images/communication/612992/image_1004100.jpg?width=640\u0026height=360","topics":[{"title":"Gene Therapy","url":"https://www.brighttalk.com/topic/gene-therapy"},{"title":"ELISA","url":"https://www.brighttalk.com/topic/elisa"},{"title":"AAV Drug Product","url":"https://www.brighttalk.com/topic/aav-drug-product"},{"title":"Capsid Titre","url":"https://www.brighttalk.com/topic/capsid-titre"},{"title":"Biologics","url":"https://www.brighttalk.com/topic/biologics"},{"title":"Biotherapeutics","url":"https://www.brighttalk.com/topic/biotherapeutics"},{"title":"Analytical Methods","url":"https://www.brighttalk.com/topic/analytical-methods"},{"title":"AAV Drug Product Development","url":"https://www.brighttalk.com/topic/aav-drug-product-development"},{"title":"Biotech","url":"https://www.brighttalk.com/topic/biotech"}],"pageState":"ondemand","visibility":"public","syndication":null,"rating":5,"ratingCount":3},"summit":{"eventCount":0,"img":"","link":"","live":[],"onDemand":[],"showTracks":false,"summitDate":"","title":"","tracks":[],"upcoming":[],"target":"","type":""},"webcastCommunities":{"communities":[{"id":230,"title":"Healthcare","description":"Healthcare","alias":"healthcare","entryCount":0,"childCount":3,"enabled":true,"primary":false,"children":[{"id":19,"title":"Medical Research","description":"The medical research community on BrightTALK brings together medical and research professionals. Find relevant webinars on medical research, laboratory science, continuing medical education and more presented by recognized medical researchers. Join the conversation by participating in live webinars and round table discussions on the latest in medical devices, medical research practices and trends in the healthcare industry.","alias":"medical-research","entryCount":2615,"childCount":0,"enabled":true,"primary":false},{"id":77,"title":"Health IT","description":"Thousands of healthcare IT professionals compose the health IT community on BrightTALK. Learn alongside them with relevant webinars on healthcare IT compliance, big data in healthcare and IT solutions for healthcare organizations. Join the conversation by asking questions and engaging with other participants during live webinars and organized discussions.","alias":"health-it","entryCount":8750,"childCount":0,"enabled":true,"primary":false},{"id":205,"title":"Life Sciences","description":"Get powerful life science insights from influential experts. Connect with thought leaders and colleagues to get the most up-to-date knowledge on strategies and initiatives to accelerate the transformation of U.S. and global health care from a volume- to value-based marketplace.","alias":"life-sciences","entryCount":2834,"childCount":0,"enabled":true,"primary":true}]},{"id":6,"title":"Research and Development","description":"The research and development community on BrightTALK brings together leading professionals in healthcare, technology and manufacturing to present on current topics in their fields. From big data in healthcare to online forensics training and medical research practices, the community is an exceptional resource for those looking to expand their knowledge. Be part of the conversation by joining the community and participating in interactive live webinars.","alias":"research-development","entryCount":32093,"childCount":1,"enabled":true,"primary":false,"children":[{"id":139,"title":"Forensic Science","description":"Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.","alias":"forensic-science","entryCount":679,"childCount":0,"enabled":true,"primary":false}]}]},"channelFeed":[{"date":"2025-09-09T08:30:00.000Z","id":621687,"channelId":10519,"thumbnail":{"alt":"Enhancing Sustainability in Biopharmaceutical Drug Development and Manufacturing","url":"https://cdn.brighttalk.com/ams/california/images/communication/621687/image_1024644.jpg?width=640\u0026height=360"},"title":"Enhancing Sustainability in Biopharmaceutical Drug Development and Manufacturing","description":"This presentation will cover the current sustainability challenges for biopharma industry and how biopharma industry should prepare to solve for this looming sustainability challenges. This talk will also indicate on some aspects of future of manufacturing processes through technological evolution.\n\nFinally, the audience will also hear on a case study which stresses on how a technology evolution and process development can enhance the sustainability issues of Biomanufacturing. \n\nThe second presentation will cover guidance of adopting Phase appropriate orthogonal high-end tools in early-stage product development and Selection of analytical tools for expedited biopharmaceutical development. This talk will provide overview on Significance of High throughput and sensitive analytical tools from Clone to Formulation ranking. This talk will also cover the contemporary challenges in HCP by ELISA and approach to defeat these challenges by alternate approach.","link":"https://www.brighttalk.com/webcast/10519/621687","status":"upcoming","duration":7200},{"date":"2025-09-04T14:00:00.000Z","id":627722,"channelId":10519,"thumbnail":{"alt":"Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information","url":"https://cdn.brighttalk.com/ams/california/images/communication/627722/image_1017546.jpg?width=640\u0026height=360"},"title":"Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information","description":"Andrey Sarafanov; PhD., Principal Investigator at U.S. FDA, Center for Biologics Evaluation and Research\nPresenting: Analytical Assessment of Leachables in Biological Drug Products: FDA Approach in Reviewing Information\n\nSandi Schaible, Executive Director, Analytical Chemistry and Regulatory Toxicology at WuXi AppTec\n\nJames Hathcock, Sr. Director, Regulatory and Validation Strategy at Cytiva","link":"https://www.brighttalk.com/webcast/10519/627722","status":"upcoming","duration":7200},{"date":"2025-04-29T14:00:00.000Z","id":633989,"channelId":10519,"thumbnail":{"alt":"Read Across Assessment for Potential Leachables Without Toxicological Data","url":"https://cdn.brighttalk.com/ams/california/images/communication/633989/image_1020531.jpg?width=640\u0026height=360"},"title":"Read Across Assessment for Potential Leachables Without Toxicological Data","description":"Presented by Yana Chervona, Drug Safety Team Lead in Drug Safety Research and Development at Pfizer","link":"https://www.brighttalk.com/webcast/10519/633989","status":"upcoming","duration":7200},{"date":"2025-04-28T14:00:00.000Z","id":636091,"channelId":10519,"thumbnail":{"alt":"Beyond USP \u003c86\u003e: Supplemental Testing","url":"https://cdn.brighttalk.com/ams/california/images/communication/636091/image_1025318.jpg?width=640\u0026height=360"},"title":"Beyond USP \u003c86\u003e: Supplemental Testing","description":"USP \u003c86\u003e, “Bacterial Endotoxins Test Using Recombinant Reagents” states, “Regulatory authorities may require supplemental data prior to acceptance…An example of supplemental data may include a comparative study of the material tested by techniques described in this chapter and those in 〈85〉.” The term, “supplemental data” may refer to the use of a statistically robust analysis of test results obtained from a single sample containing assayable levels of endotoxins activity, using both the predicate assay (\u003c85\u003e) and the candidate recombinant assay (\u003c86\u003e) .\n\nThis webinar discusses the difference between 50-200% acceptance testing and statistical equivalence. In addition, using data in the public domain as examples, the speakers will stress the importance of using a split sample containing assayable levels of contaminating or potentially contaminating endotoxins activity as the test article for these studies.","link":"https://www.brighttalk.com/webcast/10519/636091","status":"upcoming","duration":7200},{"date":"2025-04-22T14:00:00.000Z","id":635547,"channelId":10519,"thumbnail":{"alt":"Advancing Cell \u0026 Gene Quality Control with GMP Next Generation Sequencing (NGS)","url":"https://cdn.brighttalk.com/ams/california/images/communication/635547/image_1024502.jpg?width=640\u0026height=360"},"title":"Advancing Cell \u0026 Gene Quality Control with GMP Next Generation Sequencing (NGS)","description":"Full title: Advancing Cell \u0026 Gene Quality Control with GMP Next Generation Sequencing (NGS): Regulatory Insights and Industry Case Study\n\nThis webinar focuses on the established role of GMP-compliant Next Generation Sequencing (NGS) in quality control for cell and gene therapies. With evolving regulatory guidelines addressing advanced therapeutic products, NGS offers a robust and highly sensitive approach to ensure compliance and product safety.\n\nKey topics include an overview of the regulatory landscape, insights into GMP standards for cell and gene therapy products, and a real-world industry case study demonstrating the practical application of NGS. The session will address common challenges, implementation strategies, and best practices for integrating NGS into quality control workflows.\n\nDesigned for professionals in quality control, regulatory affairs, and biopharma manufacturing, this session provides valuable guidance on leveraging NGS for enhanced safety in cell and gene therapies.","link":"https://www.brighttalk.com/webcast/10519/635547","status":"upcoming","duration":7200},{"date":"2025-04-10T14:00:00.000Z","id":632663,"channelId":10519,"thumbnail":{"alt":"Design of a Global Risk-Based Personnel Monitoring Assessment for a Multi-Production Operation Company","url":"https://cdn.brighttalk.com/ams/california/images/communication/632663/image_1018250.jpg?width=640\u0026height=360"},"title":"Design of a Global Risk-Based Personnel Monitoring Assessment for a Multi-Production Operation Company","description":"Establishing a personnel monitoring (PM) program requires a risk-based approach per the current EU Annex I. Presently, there is no specific industry or regulatory guidance on how to establish sample locations and sampling frequencies using Quality Risk Management (QRM) for personnel monitoring and the methodology behind a risk-based approach can vary greatly from site to site. Implementing a global risk-based methodology is desirable for consistency. Takeda has developed a global personnel monitoring risk assessment tool that can be used across a range of production facilities. This tool applies to both gowning qualification sample site determination and routine personnel monitoring associated with batch production. Utilizing QRM principles, contamination hazards and sources were identified and assessed to inform risk scoring criteria. The personnel monitoring assessment takes into consideration the process understanding of both gowning and manufacturing operations. A case study for the application of the risk-based tool will be presented.","link":"https://www.brighttalk.com/webcast/10519/632663","status":"upcoming","duration":7200},{"date":"2025-03-27T14:00:00.000Z","id":629429,"channelId":10519,"thumbnail":{"alt":"CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy","url":"https://cdn.brighttalk.com/ams/california/images/communication/629429/image_1010978.jpg?width=640\u0026height=360"},"title":"CMC Progression from Early to Late Phase – Practical Considerations for Gene Therapy","description":"The principles for developing traditional biologics are well established, but do not always translate well to cell and gene therapy products. Creative yet practical adaptations are necessary to advance gene therapy programs toward licensure. During this presentation we will explore three key areas where practical adaptations are required:\n\nBuilding toward the commercial process: change control and managing product evolution for non-traditional development pathways, comparability challenges, and regulatory expectations\n\nMaturation of analytics – the level of product understanding expected as programs advance, method advancement from early to late phase, ensuring repeatability and robustness in method performance\n\nFinding the right partners – finding the right match in terms complementary capabilities, technical performance, phase-appropriate GMP compliance and client service infrastructure","link":"https://www.brighttalk.com/webcast/10519/629429","status":"upcoming","duration":7200},{"date":"2025-03-25T14:00:00.000Z","id":633069,"channelId":10519,"thumbnail":{"alt":"Grouping Extractable and Leachable (E\u0026L) Compounds with a Common Mechanism of Action for Toxicological Risk Assessment","url":"https://cdn.brighttalk.com/ams/california/images/communication/633069/image_1022007.jpg?width=640\u0026height=360"},"title":"Grouping Extractable and Leachable (E\u0026L) Compounds with a Common Mechanism of Action for Toxicological Risk Assessment","description":"The toxicological risk assessment of E\u0026L compounds is typically conducted on a compound-by-compound basis; however, for compounds that lack toxicity data, it may be useful to group compounds together that have similar structural and physical-chemical properties, as\nwell as a similar toxicological mechanism of action, to derive a class-specific Tolerable Intake (TI) or Permitted Daily Exposure (PDE) that is applicable for all compounds in that group. This talk explores ways to group compounds based on their structural and toxicological\nsimilarity and how to use computational models to identify a proposed toxicological mechanism of action for compounds in a group. The presentation will also review methods to conduct a cumulative risk assessment of the\ncompounds in the assembled group. This approach of first assembling a group of compounds with a common toxicological mechanism, then conducting a risk toxicological assessment of the compounds in the group, has the potential to streamline the toxicological risk assessment\nprocess when large numbers of extractable or leachable compounds are released from a polymeric material and provides a science-based method for setting TI/PDE values that is presumably less conservative than the use of Threshold of Toxicological Concern (TTC) values as default TI/PDE values for the individual compounds","link":"https://www.brighttalk.com/webcast/10519/633069","status":"upcoming","duration":7200},{"date":"2025-03-20T14:00:00.000Z","id":633019,"channelId":10519,"thumbnail":{"alt":"Microbial Impact Assessment of In-Process Bioburden Limit Excursions","url":"https://cdn.brighttalk.com/ams/california/images/communication/633019/image_1023676.jpg?width=640\u0026height=360"},"title":"Microbial Impact Assessment of In-Process Bioburden Limit Excursions","description":"Biologic manufacturing processes are vulnerable to microbial growth, requiring strong contamination controls and in-process bioburden monitoring.\n\nBioburden in-process limit excursions should be rare but when they occur, the impact from microbial impurities can be unclear. Filtration alone does not remove them and unlike endotoxin, there is no reliable way to detect the full range of microbial by-products, e.g. exotoxins, PAMPs, and proteases. From a patient safety and product quality perspective, the potential impact of microbial contamination must be assessed as part of the investigation.\n\nThe biologics industry has not harmonized on a method for conducting microbial impact assessments. This leads to inconsistency in how firms respond to in-process bioburden excursions, particularly when deciding whether to release or to discard the resulting batch.\n\nThis presentation will highlight the specific challenges and best practices for assessing the potential product quality impact of an in-process bioburden contamination, including two distinct approaches: a quantitative method built on extensive studies of Roche/Genentech, and a qualitative approach focused on process vulnerability from PDA TR. 90.","link":"https://www.brighttalk.com/webcast/10519/633019","status":"upcoming","duration":7200},{"date":"2025-03-11T14:00:00.000Z","id":632430,"channelId":10519,"thumbnail":{"alt":"Using Risk Management to Design Aseptic Process Simulations","url":"https://cdn.brighttalk.com/ams/california/images/communication/632430/image_1019757.jpg?width=640\u0026height=360"},"title":"Using Risk Management to Design Aseptic Process Simulations","description":"Using risk management to design aseptic process simulations:\n\nAnnex 1 states that “QRM (Quality Risk Management) applies to this document in its entirety”. Does this mean we can use QRM to justify non-compliance with Annex 1 requirements? The answer here is obvious: No.\n\nSo when and where can we use QRM? And for what purposes?\n\nDuring this webinar we will go through several real and practical examples for using QRM to design Aseptic Process Simulations (media fills): 1) When using QRM is not allowed, 2) When it is permitted; and 3) When it is mandatory.","link":"https://www.brighttalk.com/webcast/10519/632430","status":"upcoming","duration":7200},{"date":"2025-03-05T15:00:00.000Z","id":628817,"channelId":10519,"thumbnail":{"alt":"Big Data Strategies for Cell Therapy Manufacturing","url":"https://cdn.brighttalk.com/ams/california/images/communication/628817/image_1009881.jpg?width=640\u0026height=360"},"title":"Big Data Strategies for Cell Therapy Manufacturing","description":"Cell and gene therapy (CGT) is particularly well-suited for the application of big data analytics. Although our understanding of these complex therapies remains limited, CGT manufacturing processes and analytical methods generate substantial datasets that can be analyzed using artificial intelligence and machine learning algorithms. These advanced computational tools are instrumental in identifying critical characteristics of novel CGT products, optimizing manufacturing and analytical methods, and defining predictive biomarkers, among other applications. This presentation will discuss the role of big data in the development and manufacturing of CGT products and will explore opportunities for crowdsourcing data in the precompetitive space.","link":"https://www.brighttalk.com/webcast/10519/628817","status":"upcoming","duration":7200},{"date":"2025-02-27T15:00:00.000Z","id":629083,"channelId":10519,"thumbnail":{"alt":"Navigating the Complexities of mRNA Therapies Analysis: Challenges, Techniques, and Quality Assessment Strategies","url":"https://cdn.brighttalk.com/ams/california/images/communication/629083/image_1017356.jpg?width=640\u0026height=360"},"title":"Navigating the Complexities of mRNA Therapies Analysis: Challenges, Techniques, and Quality Assessment Strategies","description":"The approval and widespread adoption of mRNA vaccines have revolutionized the field of immunization, offering rapid and scalable solutions to combat infectious diseases. This success has spurred significant research into using mRNA for other therapies, including cell therapies, protein production, genome editing and protein replacement. Ensuring the quality and safety of mRNAs in these therapies is crucial, requiring detailed impurity profiling and advanced analytical techniques. Incorporating mRNA into drug products presents significant manufacturing and analytical challenges, particularly in maintaining the integrity of mRNA drug substances and drug products. Rigorous release and stability testing are essential to ensuring these therapeutic products remain effective and safe throughout their lifecycle.\n\nImpurity profiling is an essential part of analytical characterization for mRNA-based products. During production, both process and product impurities can arise, such as truncated mRNA fragments, double-stranded RNA (dsRNA), and residual DNA from the plasmid template. These impurities can potentially impact the drug’s performance or trigger unintended immune responses. This presentation explores the types of impurities commonly found in mRNA-based products and the advanced analytical methods used to analyze them. We will also discuss the challenges faced, potential solutions, and the importance of analytical methods in supporting development programs and meeting expanding regulatory requirements. Continuous improvements in these analytical methods are crucial to address the evolving challenges in mRNA-based drug production and to maintain high standards of safety and effectiveness.","link":"https://www.brighttalk.com/webcast/10519/629083","status":"upcoming","duration":7200},{"date":"2025-02-19T15:00:00.000Z","id":631939,"channelId":10519,"thumbnail":{"alt":"Case Study: A Risk-Based Approach to Material Transfer Validation","url":"https://cdn.brighttalk.com/ams/california/images/communication/631939/image_1016353.jpg?width=640\u0026height=360"},"title":"Case Study: A Risk-Based Approach to Material Transfer Validation","description":"Transfer of equipment and materials is identified as “one of the greatest potential sources of contamination” in cleanrooms as per EU Annex 1 (Aug 2022); therefore, effective material transfer processes within classified and critical areas play a key role in the safety and quality of products.\n\nThis presentation will describe one firm’s risk-based approach to material transfer validation. Key aspects of the approach include identifying and evaluating critical factors associated with the process of material transfer (such as impact on product contamination, impact on environmental contamination, cleanability, and materials/equipment size) and a roadmap to validation execution. Through a structured risk management framework, the critical factors are analyzed to determine their impact on contamination control, and the validation execution and maintenance ensures robust planning, testing, and lifecycle management. The result is a material transfer process integrated into the site’s contamination control strategy, supported by evidence-based validation.","link":"https://www.brighttalk.com/webcast/10519/631939","status":"upcoming","duration":7200},{"date":"2025-02-04T15:00:00.000Z","id":631998,"channelId":10519,"thumbnail":{"alt":"The Critical Role of Conversion Factor in Quantitative Determination of Host Cell DNA with dPCR","url":"https://cdn.brighttalk.com/ams/california/images/communication/631998/image_1017041.jpg?width=640\u0026height=360"},"title":"The Critical Role of Conversion Factor in Quantitative Determination of Host Cell DNA with dPCR","description":"This webinar will provide an in-depth exploration of a QbD-based method development approach for quantifying host cell DNA in gene therapy products, a critical quality attribute to ensure product safety and regulatory compliance. The session will begin by examining the measurement principles of two widely used techniques: qPCR and dPCR, while highlighting their respective advantages and limitations. A central focus will be on establishing a robust conversion factor for dPCR implementation. This factor is critical for accurately converting results from copies/μL, the standard dPCR output format, to ng/dose, as required by regulatory guidelines. The discussion will emphasize the importance of selecting an appropriate target gene and utilizing reliable reference materials to ensure precise reporting. Additionally, the webinar will address other essential aspects of method development, including sample dilution requirements, the primary sources of residual host cell DNA, and a summary of the method qualification results.","link":"https://www.brighttalk.com/webcast/10519/631998","status":"recorded","duration":2997},{"date":"2025-02-03T15:00:00.000Z","id":631663,"channelId":10519,"thumbnail":{"alt":"Deciphering Empty-Full Characterization: A Comparative Analysis of Available Analytical Methods","url":"https://cdn.brighttalk.com/ams/california/images/communication/631663/image_1023673.jpg?width=640\u0026height=360"},"title":"Deciphering Empty-Full Characterization: A Comparative Analysis of Available Analytical Methods","description":"Empty full ratio of AAV particles in a gene therapy drug is an important critical quality attribute. Due to the complexity of biological production process specifically, viral vector production mechanisms, AAV particles are quite heterogeneous. Purification process can’t entirely separate empty, partial and full particles from the process and hence a significant amount of empty and partial particles gets retained in the final product, potentially compromising quality of the product and raising safety concerns. The complexity of the challenge is understandable as the as gene therapy drugs contain multimeric protein assembly enclosing a genetic material. Where the actual process of DNA packaging remains loosely understood. There are various analytical technologies available for the characterization of these particles but almost every technology has some limitations, either in terms of the sample requirement, quality of information, precision, affordability, complexity of the assay or for their suitability in the GMP environment. AUC maintains its central role in this process and remains as a gold standard but at the same time has limited applicability across various phases of drug development due to its limited throughput and high sample requirements. There are various alternative technologies coming into play, including DLS, CDMS and Mass spectrometry, mass photometry and others. In this webinar we will discuss opportunities and challenges in various analytical technologies in characterizing this critical quality attribute of AAV vector for gene therapy.","link":"https://www.brighttalk.com/webcast/10519/631663","status":"recorded","duration":3524},{"date":"2025-01-16T15:00:00.000Z","id":624135,"channelId":10519,"thumbnail":{"alt":"Leveraging Instrumentation to Accelerate Release Testing \u0026 Minimize Human Input","url":"https://cdn.brighttalk.com/ams/california/images/communication/624135/image_1017023.jpg?width=640\u0026height=360"},"title":"Leveraging Instrumentation to Accelerate Release Testing \u0026 Minimize Human Input","description":"Presented by Therese Choquette, Head of Analytical and Translational Sciences at Tigen Pharma\n\nThis talk will focus on the analytical testing needed for the release of cell and gene therapy products. A lot of focus has been on improvements and automation of equipment used in manufacturing of cell therapies such as bioreactors. However, to improve and speed up the release testing, this needs to be done also on the analytical side.\n\nToday, in most Quality Control labs, the instruments and methods that are used for in-process and release testing are high throughput (bigger sized instruments) and require experienced analysts for the execution of the test, for example in flow cytometry. The preparation of the sample involves manual manipulation, such as for the potency assay, sometimes very extensive and lengthy before ready to be tested. Once the test is performed, the data needs to be analyzed and calculated for the reportable results, it may for example be from an ELISA for cytokines or the genetic transduction by PCR. The entire procedure from the sample preparation to the data analysis for the results provides opportunities for errors, and the manipulation of the samples can have an impact on the cells. This may decrease the precision of the assay and potentially cause Out Of Specification and delay of product release. \n\nDepending on each specific product, different analytical tests and assays are required for the release of the product. However, safety tests for determination of absence of mycoplasma, endotoxin, and bacterial and fungal contamination are mandatory for all products. No matter the type of tests or assays, there is a need for faster and less hands-on technology. Using automated instruments and methods with less manipulation of the sample and automated data analysis, offers opportunities to reduce time and costs for the release testing, as well as providing assays with improved performance and less prone for errors.","link":"https://www.brighttalk.com/webcast/10519/624135","status":"recorded","duration":9179},{"date":"2024-12-04T14:30:00.000Z","id":623717,"channelId":10519,"thumbnail":{"alt":"Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development","url":"https://cdn.brighttalk.com/ams/california/images/communication/623717/image_1014649.jpg?width=640\u0026height=360"},"title":"Current Status and Overview of the RMM and Endotoxin Microbiology USP Chapters under Development","description":"Jay Bolden, Senior Director, Eli Lilly and Company Global Quality Laboratories. Presenting:\nAn Overview of Recent USP Bacterial Endotoxins Standards Development\n\nDr David Roesti, PhD. Microbiologist/Facilitator QA/QC at Novartis Pharma AG. Presenting:\nOverview and Future Plans of the USP Rapid Microbiological Methods Subcommittee\n\nVeronika Wills, Manager, Technical Services at Associates of Cape Cod, Inc\nPresenting: Early Implementation of Recombinant Cascade Reagent PyroSmart NextGen® in Line With USP \u003c86\u003e\n\nNicola Reid, Associate Director of Endotoxin Products, Charles River\nPresenting: A 3-Step Validation Blueprint for Recombinant Method Implementation\n\nLamin Jallow, Microbiology Technology Specialist at Merck KGaA\nPresenting: Early detection of microbial contaminants in cell-based products using the Milliflex® Rapid System\n\nFélix Montero-Julian, Scientific Director of Pharma Quality Control at bioMérieux\nPresenting: Implementation of BACT/ALERT® 3D in light of the USP \u003c72\u003e Chapter: Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products\n\nFollowed by a live Questions and Answers session.","link":"https://www.brighttalk.com/webcast/10519/623717","status":"recorded","duration":12209},{"date":"2024-11-14T15:00:00.000Z","id":622712,"channelId":10519,"thumbnail":{"alt":"Process Equipment Related Leachable Compounds - 3 Case Studies","url":"https://cdn.brighttalk.com/ams/california/images/communication/622712/image_1008970.jpg?width=640\u0026height=360"},"title":"Process Equipment Related Leachable Compounds - 3 Case Studies","description":"Process Equipment Related Leachable Compounds – 3 case studies\n\nCase 1: Over sterilized filter, 3 days instead of 3 hours – process leachable compounds in the parenteral drug product\n\nCase 2: Solid, white, 5 mm flakes in process equipment – effects on the parenteral drug products\n\nCase 3: What is wrong with the process equipment? – PERL investigation continued as a stopper related leachable analyses.","link":"https://www.brighttalk.com/webcast/10519/622712","status":"recorded","duration":6744}],"isSessionCookiePresent":false,"envVariables":{"hostUrl":"https://www.brighttalk.com","gtmId":"GTM-WL9H26","envValue":"prod","cloudinaryEnv":"brighttalkprod","staticAssetCdnUrl":"https://assets.brighttalk.com","nextPublicSentryDSN":"https://85b928fa6c7a4e9985f029323783cd54@o311348.ingest.sentry.io/5438623"}},"__N_SSP":true},"page":"/[channelId]/[webcastId]","query":{"utm_source":"888PublishingLtd","utm_medium":"brighttalk","utm_campaign":"612992","channelId":"10519","webcastId":"612992"},"buildId":"1797","assetPrefix":"/webcast","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[12910,75479,93394],"gssp":true,"appGip":true,"scriptLoader":[]}</script><script> window.dataLayer = window.dataLayer || []; dataLayer.push({ 'brighttalk-page-name': 'webcast', 'brighttalk-portal-is-logged-in': false });</script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WL9H26');</script><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-WL9H26" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript></body></html>